Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ocella
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Ocella is a biotechnology company focused on developing next-generation "off-the-shelf" cell therapies using induced pluripotent stem cell (iPSC) technology. The company leverages a proprietary, non-viral, protein-based reprogramming platform to generate high-quality, clinical-grade iPSCs and their derivatives. Founded by leading stem cell researchers from Johns Hopkins University, Ocella aims to overcome the limitations of current autologous cell therapies by providing scalable and standardized cellular products. The company's technology is designed to produce various therapeutic cell types for applications in oncology, hematology, and regenerative medicine.
- Therapeutic areas
- OncologyOtherHematology
- Modalities
- Cell therapyStem cell therapyInduced pluripotent stem cell derived therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Ocella.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocella.